Cargando…

PD-1 checkpoint blockade in advanced melanoma patients: NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidates

Blockade of the PD-1 receptor has revolutionized the treatment of metastatic melanoma, with significant increases in overall survival (OS) and a dramatic improvement in patient quality of life. Despite the success of this approach, the number of benefitting patients is limited and there is a need fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pico de Coaña, Yago, Wolodarski, Maria, van der Haar Àvila, Irene, Nakajima, Takahiro, Rentouli, Stamatina, Lundqvist, Andreas, Masucci, Giuseppe, Hansson, Johan, Kiessling, Rolf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7470181/ https://www.ncbi.nlm.nih.gov/pubmed/32939320 http://dx.doi.org/10.1080/2162402X.2020.1786888

Ejemplares similares

Predicting anti-PD-1 responders in malignant melanoma from the frequency of S100A9+ monocytes in the blood
por: Rad Pour, Soudabeh, et al.
Publicado: (2021)

High expression of ID1 in monocytes is strongly associated with phenotypic and functional MDSC markers in advanced melanoma
por: Melief, Jeroen, et al.
Publicado: (2020)

Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma
por: de Coaña, Yago Pico, et al.
Publicado: (2017)

Ipilimumab treatment decreases circulating Tregs and GrMDSC while enhancing CD4+ T cell activation
por: Pico de Coaña, Yago, et al.
Publicado: (2015)

Ipilimumab treatment enhances CD4+ T cell activation while decreasing Treg and MDSC frequency in advanced melanoma patients
por: Pico de Coaña, Yago, et al.
Publicado: (2014)

In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma
por: Babačić, Haris, et al.
Publicado: (2020)

Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid derived suppressor cells as well as their arginase1 production
por: Gentilcore, Giusy, et al.
Publicado: (2014)

Self-Delivering RNAi Targeting PD-1 Improves Tumor-Specific T Cell Functionality for Adoptive Cell Therapy of Malignant Melanoma
por: Ligtenberg, Maarten A., et al.
Publicado: (2018)

Features of Memory-Like and PD-1(+) Human NK Cell Subsets
por: Della Chiesa, Mariella, et al.
Publicado: (2016)

Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion
por: Alvarez, Maite, et al.
Publicado: (2020)

Monocyte subsets associated with the efficacy of anti‑PD‑1 antibody monotherapy
por: Ohkuma, Ryotaro, et al.
Publicado: (2023)

PD-L1 blockade enhances anti-tumor efficacy of NK cells
por: Oyer, Jeremiah L., et al.
Publicado: (2018)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Imbalance of Circulating Monocyte Subsets and PD-1 Dysregulation in Q Fever Endocarditis: The Role of IL-10 in PD-1 Modulation
por: Ka, Mignane B., et al.
Publicado: (2014)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

Interferon β and Anti-PD-1/PD-L1 Checkpoint Blockade Cooperate in NK Cell-Mediated Killing of Nasopharyngeal Carcinoma Cells
por: Makowska, Anna, et al.
Publicado: (2019)

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
por: Zheng, Peilin, et al.
Publicado: (2015)

Genetic biomarkers for PD-1/PD-L1 blockade therapy
por: Kataoka, Keisuke, et al.
Publicado: (2016)

Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
por: Brancatella, Alessandro, et al.
Publicado: (2021)

Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
por: Brancatella, Alessandro, et al.
Publicado: (2021)

Reconstitution of Monocyte Subsets and PD-L1 Expression but Not T Cell PD-1 Expression in Obstructive Sleep Apnea Patients upon PAP Therapy
por: Polasky, Christina, et al.
Publicado: (2021)

Expression of Concern: Imbalance of Circulating Monocyte Subsets and PD-1 Dysregulation in Q Fever Endocarditis: The Role of IL-10 in PD-1 Modulation
Publicado: (2022)

Regulation of myeloid cells by activated T cells determines the efficacy of PD-1 blockade
por: Eissler, Nina, et al.
Publicado: (2016)

PD-1/PD-L1 checkpoint blockade harnesses monocyte-derived macrophages to combat cognitive impairment in a tauopathy mouse model
por: Rosenzweig, Neta, et al.
Publicado: (2019)

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
por: Hamanishi, Junzo, et al.
Publicado: (2016)

Oncolytic virus and PD-1/PD-L1 blockade combination therapy
por: Chen, Chun-Yu, et al.
Publicado: (2018)

Drug response to PD-1/PD-L1 blockade: based on biomarkers
por: Chen, Qi, et al.
Publicado: (2018)

Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
por: Zhao, Bin, et al.
Publicado: (2020)

Clinical PD-1/PD-L1 Blockades in Combination Therapies for Lymphomas
por: Katsuya, Hiroo, et al.
Publicado: (2023)

Analysis of PD-1 expression in the monocyte subsets from non-septic and septic preterm neonates
por: Zasada, Magdalena, et al.
Publicado: (2017)

Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
por: Grecea, Miruna, et al.
Publicado: (2021)

PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells
por: Pesce, Silvia, et al.
Publicado: (2019)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
por: Bocanegra, Ana, et al.
Publicado: (2020)

From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
por: Zhao, Xuan, et al.
Publicado: (2022)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
por: Kamada, Takahiro, et al.
Publicado: (2019)

Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade
por: Jiang, Youhai, et al.
Publicado: (2020)

Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle
por: Zhuang, Yuan, et al.
Publicado: (2020)

Targeting Tim-3 in Cancer With Resistance to PD-1/PD-L1 Blockade
por: Tian, Tian, et al.
Publicado: (2021)

Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade
por: Zhang, Min, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_v3kassoh42u7ntcou3tb9egsb7